InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,253.30
(
0.01%
)
Post# of 252302
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Mufaso

Send PM Follow Ignore
Followers 31
Posts 464
Boards Moderated 0
Alias Born 01/08/2008

Mufaso

Member Level

Re: rfj1862 post# 247309

Saturday, 06/03/2023 4:02:11 PM

Saturday, June 03, 2023 4:02:11 PM

Post# of 252302
VKTX- I agree VK-0214 is a significant overlooked Viking asset.

However I was expecting the results for the 1b trial in X-ALD more towards the end of the year (e.g. 4th q) rather than the next few months. I am thinking this because the 1b trial was still enrolling as of the 1st q cc which was 4-26. CEO Brian Lian in his prepared remarks then said:

The current phase 1b study is enrolling adult males and will run 28 days…With our VK0214 program, we continued enrolling our Phase 1b study in patients with adrenomyeloneuropathy and we anticipate reporting data from this study later in the year.

"People are best convinced by reasons they discover themselves"

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up